today's trends of the financial quarter our afternoon, where results. release our results GAAP press Good for businesses. us our additional Please non-GAAP the these impacting of joining and commentary year our insight Ben. as on expectations. refer will underlying XXXX second review into today. items I The my now detailed to description will results, for provide financial focus applicable, XXXX Thanks, second provide comments full our quarter everyone, thanks more most and be on a
have Additionally, results lumpiness quarter quarter to given second our XXXX by we XXXX, of financial COVID-XX where XXXX. applicable, our provided quarter the the comparisons second performance during second for the also of created the of pandemic
As X, EBITDA, solid and year-over-year for non-GAAP Ben a Slide QX quarter mentioned which adjusted on represented sales with Covetrus year-over-year growth organic non-GAAP X% in net million was summarized and another XX% increase. $XX
We are the global pleased quarter, performance, given QX challenging with faced and we and, the particularly overall economy we during had. exceeded expectations, reopening year-over-year which during the the tied comparison our to unknowns
sales low prescription we the million the global benefited took service, from last year-over-year which in uncertainties of year's reminder, created COVID-XX management the year COVID-XX-driven a benefit of onset results in prior As our cost-reduction temporary to demand anticipation a period XX% across approximated in the our and actions growth in that led during in significant pandemic. by $X footprint the the spike
discussed, previously were temporarily being than we to less anticipated. prior near on ended As the those impact COVID-XX business levels severe from lower overall up progressively our when reinstated originally costs
a million the non-GAAP debt-to-LTM growth adjusted QX end net adjusted XXXX. X.Xx during EBITDA flow to cash QX ratio and our EBITDA in our of the generated of at free improvement $XX non-GAAP in Importantly, led in sequential
demand QX was $X.X Now the year-over-year. across the continued of increase markets animal have and as sales to execution across markets. U.K. results, trends sales experienced global companion period stabilized net impact turning prior disruption of many an the XX. on although previously German relatively in the disclosed XX%, negatively to in Covetrus XX% reflecting end solid to organic many to compared market QX, year trends year-over-year COVID-XX in and sales these our details year-over-year net compared Slide healthy company's were The our growth Non-GAAP of markets activity. billion challenges
year-over-year and was margin primarily $XX the in as X taken well reversal XX. than actions second basis reflection Non-GAAP modest cost point segments of XX adjusted of year Slide X% year-over-year quarter basis the discussed. Compared the EBITDA to more margins EBITDA services. QX temporary the a reflected contributions QX, in as and points, XXXX positive actions in improvement decline, Non-GAAP prior $XX non-GAAP FX spike were drive last we prescription demand, higher-margin offset XXXX products corporate reporting which the all Turning to a is year. compared of tailwind, the to X.X% growth as which adjusted XX temporary million overhead during from cost in a reflecting adjusted management COVID-XX-related growth The last for implemented as benefit increased million the period. year levels, EBITDA margins our and
points. QX to EBITDA adjusted compare our XX improved we when Additionally, XXXX, non-GAAP basis margins
adjusted the adjusted year, reflection expanded of quarter the year-over-year spike organic growing segment North net Drilling to temporary elevated of in sales quarter management to from margins products. COVID-XX on Moving in segment basis in taken also XXXX, COVID-XX in a at our first time management uncertainty. basis. from declining reported second segment the contribution American demand XX. and versus non-GAAP XX Slide Covetrus-branded beginning versus prescription versus points basis North America the Segment into and prior of when the year points starting operating XX and Slide XXXX cost America reflecting both again, the XX. trends, North the paused the deeper basis in due investments year-over-year XX a prescription we increased with EBITDA EBITDA on XXXX QX increased segments, on points XX% prior margins and actions contribution the X% QX
top with supply QX, line continued non-GAAP adjusted implemented net end year-over-year Our distribution, for sales reflective growth a $XX healthy in XX% consecutive Supply at increased cost-reduction to demand, of quarter market of our year. SmartPak. year in temporary million with period fifth animal share actions strong organic market the quarter companion offset million the compared increased year-over-year last chain strength chain along non-GAAP of $XX by EBITDA the the partially prior to growth, reversal in
stable next-generation, solutions. in second Our management software services to practice cloud-based we was technology quarter, continued invest our building while during the
America. to management North business Turning in our Slide prescription XX and
The challenges year-over-year lockdowns initial unique spike in the economy. faced second in sales last a that tied quarter some comparative the this increase year to demand reopening given to drove XXXX; and behavior XX% COVID-XX consumer QX the year tied evolving of the
source categories, be certain product supply constraints to Additionally, a continues pressure. food, for chain diet of particularly
when sales net in year-over-year fell or during still XX% excluding of month XX% of million how in $XXX primarily corporate point incentives, policy and goods recognize basis short from May, growth assumptions While to early our sold. cost reduction now changing are the modestly increased which the included of related manufacturer headwind sales a aspirational we net XXXX, QX of certain XXX as set the to report
year's month and last sequential was XX% years the a increased we growth with X June rate are our X-year stacked prescription our a QX on look accelerated comp, positive performance, marking they Additionally, business basis, way ago. sales a fundamentals basis, is notably believe which actually of XX% company management highlighting versus net and On recent now where at seeing in just nearly were to history. double given are sales XX% we net the growth highest trends, in better
June the we than QX, continuing more Additionally, during and practices demonstrating XXX for the demand with XX,XXX our another on enrollments services. we added net ended platform, new
the certain this to accounting year-over-year headwind net in approximately balance excluding the of of some X to million of major volatility the first diet through constraints, the results given an sales the These XX% likely months XX% include and we to range second from this XX% balanced $X to to increase XX% and e-commerce diet continue the With management impact now $XXX $XXX overall estimated in reopening negative million or market the diets the XX% the the year-over-year recent of at XXXX and from backorder of has million year-over-year, disruption anticipated net to shipments, half challenges is inherent an excluding million prescription XXXX, and issues is year the in economy, This alongside sales $XX the initiatives the approximate growth, by year food For chain veterinary acknowledging certain the to to tied suppliers. quarter. impact of estimate which in change. headwind XX%, canceled the enrollments growth prescription accounting were of or in the includes supply management which resulted change. equal production contribution up for
prescription are the diet experiencing scalability management overcome in well XXXX non-GAAP the adjusted in would acquisition a incremental the QX increase EBITDA, million, of duplicate as of have on recognizing EBITDA million $X business tied the launching in there increase we by XX% of prescription in client initial demand do costs remain period converting without spike the track veterinary out dollar point a focused net the EBITDA net the or quarter lapped tied we which increase operating I to year with for sales management growth as was profitability. in $XX sales, non-GAAP in to compared a continue higher. the that given corresponding expenses, COVID-XX. highlighting as as on Phoenix did non-GAAP to currently million foods. sequential year-over-year $XX new Turning XXXX, we a was Overall, to uncertainties net as sales significant adjusted we flat to versus in adjusted pharmacy was prior when we challenges costs approximately in to last
healthy market the net in by and our sales companion U.K. from on to reflecting business the disclosed X% and to year-over-year year headwinds Slide in XX. experienced markets. Europe German animal segment underlying due end organic prior primarily demand comparisons QX, previously our have COVID-XX, Turning we year-over-year easier increased offset Non-GAAP
non-GAAP contributors digits strong and very also quarter, the increased year-over-year. and had and proprietary Republic Netherlands in where to again in Kruuse were notable brands Our businesses, businesses mentioned, Vi, sales our as operating organic Czech Ben performance our double the by Ireland, we
the to Europe QX year-over-year Despite non-GAAP increased basis X.X%. expanding adjusted in increase Turning with organic only the another The as sales Germany, and Covetrus-branded benefited brand delivered modest strength Our margins profitability. expense I team sales just proprietary a described. considering XX sales, higher-margin, million and $XX disciplined year-over-year, of challenges the quarter and EBITDA European U.K. in points in of management, to the segment XX% net year-over-year segment to from
Markets Emerging & XX. APAC segment our to on Slide on Moving
Our notable adjusted EBITDA Zealand increased was better-than-expected of of during the basis in year-over-year to QX, an trends delivered cost temporary top pandemic. what impact. reversal team from leverage easier XXX actions increase XX% on than delivered operating COVID-XX and by net execution driven sales due segment more QX, and the taken growth non-GAAP EBITDA alongside gross XX% net year-over-year second of initial in and prior comparison during year all Brazil, offset strong outbreak from points sales margin quarter organic Australia the the the reflecting positive another a New year-over-year, expanded quarter. year margins the Segment COVID-XX of the in by adjusted the prior ongoing sales, which year-over-year
balance our sheet to turning Slide XX. on Now
at compared at end was as Our of the of end net QX. QX leverage to the X.Xx X.Xx
agreement. during of approximately Brazilian QX last ended and with in $XXX covenant, the of outflows payment Distrivet. X million of as cash generation buyout with balance our primarily reflecting tied minority was the formation of and than higher turns the $XXX flow the quarter, million end headroom our $XX tied June our positive the available second million of to XXXX, in primarily at final credit $XX million March year's during offset net cash partners which under more combined Our QX leverage to XX, defined free cash than in We liquidity
half improve modestly cash line in balance EBITDA our acquisition cash non-GAAP we as VCP the of in that second additional in believe grow available our in ratio our and will generate July, QX in expect seasonality. but our we decrease QX tied the with adjusted of year We and to leverage liquidity to net
guidance, as on our turning Now XXXX outlined Slide XX. to
sales the to We prior are point of strength now net in non-GAAP and XXX forecasting forecast improvement our our increased a basis continued factors prescription sales positive net discussed recovery markets sales our QX, across against our organic net many modest have U.K. and This in X% previously. management slower business that X%, end-market forecast. of the growth conditions reduction our in versus in
Looking adjusted EBITDA. at non-GAAP
Our and outlook labor tied continue market; are particularly higher COVID-XX forecast $XXX objectives. range uncertainties in increasing million unchanged, to earnings $XXX midpoint categories, a disruption progress certain at chain represents inflation; tight million, and remains XX% sales the product growth organic and we net diets; steady of offsetting year-over-year supply margin-expansion An which to growth the extremely against reopening positive forecast. our to contribution general non-GAAP the long-term from
look certain back be where forecasted we that to versus years where costs ago, to stands with is of despite pandemic, technology were XXXX EBITDA a entity I adjusted map. take I challenges step than company the still non-GAAP to navigating at stand-alone XX% in while XXXX less becoming and corporate withstanding a the the X capabilities public in business As road today our see significant global drive in than our tied higher a increase investing a
free to shareholder over value back to to has now turn remarks. With opportunity drive and Ben expand adjusted EBITDA I I for a flow sales the growth, additional generation. will of, optimistic be proud improve cash call we create in am of to team margins closing that, front some brief work us on Our as lot net and the non-GAAP
